{
    "nct_id": "NCT03815058",
    "official_title": "A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma",
    "inclusion_criteria": "* Histologically confirmed metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage IIIC or IIID) cutaneous, acral, or mucosal melanoma;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n* Life expectancy >/= 12 weeks;\n* Adequate hematologic and end-organ function;\n* Naive to prior systemic anti-cancer therapy for advanced melanoma with some exceptions;\n* Tumor specimen availability;\n* Measurable disease per RECIST v1.1.\n\nExclusion criteria:\n\n* Ocular/uveal melanoma;\n* Any anti-cancer therapy with the exceptions as specified in the protocol;\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;\n* Previous splenectomy;\n* History of autoimmune disease;\n* Prior allogeneic bone marrow transplantation or prior solid organ transplantation;\n* Positive test for Human Immunodeficiency Virus (HIV) infection;\n* Active hepatitis B or C or tuberculosis;\n* Significant cardiovascular disease;\n* Known clinically significant liver disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}